Interferon treatment for chronic hepatitis C in patients infected by the immunodeficiency virus;TRATAMIENTO DE LA HEPATITIS CRONICA C CON INTERFERON EN PACIENTES INFECTADOS POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA

Medicina Clinica

Volumn 106, Issue 13, 1996, Pages 486-490

  Soriano, V ^a,b   Garcia Samaniego J ^a   Bravo, R ^a   Gonzalez J ^a   Castro, A ^a   Martinez Odriozola P ^a   Colmenero, M ^a   Carballo, E ^a   Suarez D ^a   Castilla, J ^a   Rodriguez Pinero F J ^a   Moreno, A ^a   Del Romero, J ^a   Pedreira, J ^a   Gonzalez Lahoz J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Rafael Calvo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ALPHA2B INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVERSE DRUG REACTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; FEMALE; HEPATITIS C; HUMAN; INTRON; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; T LYMPHOCYTE; AIDS RELATED COMPLEX; CHI SQUARE DISTRIBUTION; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PROSPECTIVE STUDY; REVIEW; SERODIAGNOSIS; SPAIN; TIME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; INTERFERON ALFA-2B; MALE; PROSPECTIVE STUDIES; SPAIN; TIME FACTORS;

EID: 18744419079     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Miró JM, Buira E, Mallolas J, Gallart T, Moreno A, Zamora I et al. Linfocitos CD4+ e infecciones oportunistas y neoplasias en pacientes con infección por el virus de la inmunodeficiencia humana. Med Clin (Barc) 1994; 102: 566-570.
2. Moore R, Hidalgo J, Sugland B, Chaisson R. Zidovudine and the natural history of the acquired immunodeficiency syndrome N Engl J Med 1991; 324: 1.412-1.416
3. Vella S, Giuliano M, Pezzotti P. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992; 267: 1.232-1.236
4. Graham N, Zeger S, Park L The effects on survival of early treatment of HIV infection N Engl J Med 1992; 326: 1.037-1.042
5. Soriano V, Valencia E, Alba A, Laguna F, Moreno V, García-Samaniego J et al Cambios en el espectro de enfermedades en pacientes hospitalizados con infección por VIH Med Clin (Barc) 1993; 101: 736-740
6. Escartín P, López G, García C. El espectro de la hepatopatía en la infección por el virus de la inmunodeficiencia humana: estudio de 50 biopsias hepáticas. Med Clin (Barc) 1991; 97: 201-205
7. Soriano V, García-Samaniego J, Bravo R, Valen cia E, Laguna F, De Pauplana M et al. Morbilidad y mortalidad asociadas a hepatopatía crónica viral en pacientes infectados por el virus de la inmunodeficiencia humana Med Clin (Barc) 1995; 104: 641-644
8. Soriano V, García-Samaniego J, Bravo R, Gutiérrez M, González-Lahoz J High morbidity and mortality with chronic viral liver disease in HIV- infected individuals in Spain J Infect 1994; 28: 100-101
9. Jover R, Gutiérrez A, Boix V, Portilla J Mortalidad por enfermedad hepática crónica en pacientes con infección por VIH. Med Clin (Barc) 1995; 105 38.
10. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C et al A comparison of three interferon alfa-2b regimens for the long- term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1.457-1.462
11. Davis G. Interferon treatment of cirrhotic patients with chronic hepatitis C: a logical intervention Am J Gastroenterol 1994; 89: 658-660.
12. Subdirección General de Prestaciones y Evaluación de Tecnologías Samtarias Tratamiento con interferón en las hepatitis crónicas Med Clin (Barc) 1994; 103: 498-504.
13. Soriano V, García-Samaniego J Interferón en la hepatitis crónica de sujetos infectados por el VIH: ¿sí o no? Med Clin (Barc) 1992; 99: 459- 461
14. Marcellin P, Boyer N, Giostra E. Degott C, Couroucé A, Degos F Recombinant human IFN in patients with chronic non A-non B hepatitis a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397.
15. Boyer N, Marcellin P, Degott C, Degos F, Saimot A, Erlinger S Recombinant interferon alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992; 165: 723-726.
16. Aguilar Y, Antúnez JM, Castaño M, Jiménez-Oñate F. Tratamiento de las hepatitis crónicas en pacientes positives para VIH Med Clin (Barc) 1993; 101: 238.
17. Marriott E, Navas S, Del Romero J, García S, Castillo I, Quiroga JA et al Treatment with recombinant interferon of chronic hepatitis C in anti-HIV positive patients J Med Virol 1993; 40: 107-111.
18. Knodell R, Ishak K, Black W Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435
19. Di Bisceglie A, Hoofnagle J. Therapy of chronic hepatitis C with alfa-interferon: the answer? or more questions? Hepatology 1991; 13: 601-603
20. Gordon S, Veneri R, McFadden R, Reddy K, Schiff E. Major hemorrhage after percutaneous liver biopsy in patients with AIDS. Gastroenterology 1991; 101: 1.787.
21. Lau J, Davis G, Kniffen J. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C Lancet 1993; 341: 1.501-1.504
22. Stuyver L, Rossau R, Wyseur A Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1.093-1.102.
23. Van Doom L, Kleter B, Stuyver L. Analysis of hepatitis C virus genotypes by a line probe assay (LIPA) and correlation with antibody profiles Hepatology 1994; 21: 122-129.
24. Stuyver L, Van Arnhem W, Wyseur A. Hernández F, Delaporte E. Maertens G. Classification of HCV based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of 5 additional subtypes. Proc Natl Acad Sci USA 1994; 91: 10.134-10.138
25. Soriano V, De Pouplana M, Nedjar S, Tor J, Hewlett I, Ribera A et al. Marcadores serológicos y genómicos del virus de la hepatitis C en receptores de transfusiones con hepatitis no A no B Med Clin (Barc) 1991; 97: 764-768
26. Simmonds P, Holmes E, Cha T Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2.391- 2.399.
27. Andreu J, Sánchez-Quijano A, Gavilán F, Luque F, Soto B, Medrano FJ et al. influencia de la coinfección por VIH en el curso evolutivo de la infección crónica por el virus de la hepatitis C. Gastroenterol Hepatol 1994; 17: 230.
28. Thomas D, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212-220
29. Soriano V, Bravo R, García-Samaniego J, González J, Martínez-Odriozola P, Arroyo E et al CD4+ T-lymphocytopenia in HIV-infected patients ongoing interferon therapy for chronic hepatitis C. AIDS 1994; 8: 1.621-1.622.
30. Webster A. Virus infections in primary immunodeficiency J Clin Pathol 1994; 47: 965-967.
31. Bjoro K, Froland S, Yun Z, Samdal H, Haalan T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immunoglobulin N Engl J Med 1994; 331: 1.607-1.611
32. Martin P, Di Bisceglie A, Kassianides C, Lisker- Melman M, Hoffnagle J. Rapidly progressive Non-A, Non-B hepatitis in patients with HIV infection Gastroenterology 1989; 97: 1.559- 1.561.
33. Eyster M, Diamondstone L, Lien J, Ehmann W, Quan S, Goedert J. The natural history of hepatitis C virus (HCV) infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus (HIV) J AIDS 1993; 6: 602-611
34. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555-561
35. Libanore M, Bicocchi R, Sighnolfi L, Ghinelli F. Fulminant NANB hepatitis in a patient with AIDS, a possible demonstration of direct hepatic damage by the virus/es involved. Infection 1988; 16: 255.
36. Haverkos H, Lange W. Serious infections other than HIV among intravenous drug abusers. J Infect Dis 1990; 161: 894-902.
37. Horvath J, Raffanti SP Clinical aspects of the interactions between HIV and the hepatotropic viruses Clin Infect Dis 1994; 18: 339-347.
38. Quan C, Krajden M, Grigonew G, Salit I Hepatitis C in HIV-infected patients. Clin Infect Dis 1993; 17: 117-119.
39. Soriano V, Valencia E, Laguna F, González-Lahoz J. High morbidity and mortality associated with Non-AIDS defining conditions in HIV-infected patients in Spain. Genitourin Med 1994; 70: 355-356
40. Stein M, O'Sullivan P, Wachtel T, Fisher A, Miko lich D, Sepe S et al. Causes of death in persons with HIV infection. Am J Med 1992; 93: 387- 390.
41. Davis G, Balart L, Schiff E et al Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial N Engl J Med 1989; 321: 1.501-1.505.
42. Di Bisceglie A, Martin P, Kassianides C Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo- controlled trail N Engl J Med 1989; 321: 1.506-1.510
43. Shindo M, Aral K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long- term response to interferon therapy Ann Intern Med 1995; 122: 586-591
44. Soriano V, Nedjar S, García-Samaniego J, Bravo R, Castro A, González J et al. High rate of co-infection with different hepatitis C virus genotypes in intravenous drug addicts in Spain. J Hepatol 1995; 22: 598.
45. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H et al Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-883.
46. Davis G, Lindsay K, Albrecht J, Bodenheimer H, Balart L, Perrillo R et al. Predictors of response to recombinant interferon treatment in patients with chronic hepatitis C Hepatology 1990; 12: 905.
47. Causse X, Godinot H, Chevallier M. Comparison of 1 or 3 MU interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502
48. Tsubota A, Chayama K, Ikeda Y, Yasuji A, Koida I, Saitoh S et al. Factors predictive of response to interferon therapy in hepatitis C virus infection Hepatology 1994; 19: 1.088-1.094.
49. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
50. Camps J, Crisóstomo S, García-Granero M, Riezu-Boj J, Civeira P, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34: 1.714-1.717.
51. Camps J, García-Granero M, Rieju-Boj J, Larrea E, de Álava E, Civeira MP et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994; 21: 4-11.
52. Davis P. Prediction of response to interferon treatment of chronic hepatitis C J Hepatol 1994; 21: 1-3.
53. Kanai K, Kaho M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1.543
54. Yoshioka K, Kakamu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy, relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-299
55. Lane HC, Davey V, Kovacs J, Feinberg J, Metcalf J, Herpin B et al Interferon-alpha in patients with asymptomatic HIV infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 805-811.
56. Johnson V, Barlow M, Merrill D, Chou T, Hirsch M Three drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon alpha-2a. J Infect Dis 1990; 161: 1.059-1.067.
57. Brook M, Gor D, Forster S, Harris W, Jeffries D, Thomas H. Suppression of HIV p24 antigen and induction of HIV anti-p24 antibody by alpha-interferon in patients with chronic hepatitis B. AIDS 1988; 2: 391-393.
58. Krown S, Gold J, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B et al Interferon with zidovudine: safety, tolerance, and clinical and virological effects in patients with Kaposi's sarcoma associated with the Acquired Immunodeficiency Syndrome (AIDS) Ann Intern Med 1990; 112: 812-821.
59. Lane HC, Kovacs J, Feinberg J. Antirretroviral effects of interferon in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2: 1.218-1.222
60. 6/l: results of the Zidon trial. AIDS 1995; 9: 1.025-1.036.
61. Lutero M, Balsano C, Natoli G. Hepatitis B virus X proteins transactivate long terminal repeats HIV types 1 and 2. J Virol 1990; 64: 3.082- 3.086.
62. Greenspan D, Greenspan J, Overby G. Risk factors for rapid progression from hairy leukoplaquia to AIDS: a nested case-control study J AIDS 1991; 4: 652-658
63. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4+ cells after IFNa treatment in HIV-1 infection. Lancet 1993; 341: 958-959.
64. Pesce A, Taillan B, Rosenthal E. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341: 1.597